Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis Results Through Week Twenty-Four of the GO-VIBRANT Study

被引:96
作者
Kavanaugh, Arthur [1 ]
Husni, M. Elaine [2 ]
Harrison, Diane D. [3 ]
Kim, Lilianne [3 ]
Lo, Kim Hung [3 ]
Leu, Jocelyn H. [3 ]
Hsia, Elizabeth C. [3 ,4 ]
机构
[1] Univ Calif San Diego, La Jolla, CA 92093 USA
[2] Cleveland Clin, Cleveland, OH 44106 USA
[3] Janssen Res & Dev LLC, 1400 McKean Rd,POB 776, Spring House, PA 19477 USA
[4] Univ Penn, Philadelphia, PA 19104 USA
关键词
NECROSIS-FACTOR-ALPHA; EVERY; 4; WEEKS; DOUBLE-BLIND; ANKYLOSING-SPONDYLITIS; RHEUMATOID-ARTHRITIS; METHOTREXATE THERAPY; PHASE-III; RECOMMENDATIONS; ANTIBODY; MULTICENTER;
D O I
10.1002/art.40226
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To evaluate the safety and efficacy of intravenous (IV) golimumab treatment in psoriatic arthritis (PsA). Methods. In this phase III, randomized, double-blind, placebo-controlled trial, patients were randomly assigned to receive IV placebo (n = 239) or golimumab at 2 mg/kg (n = 241) at weeks 0, 4, 12, and 20. The primary end point was the proportion of patients meeting the American College of Rheumatology 20% improvement criteria (achieving an ACR20 response) at week 14. Controlled secondary end points included change from baseline in Health Assessment Questionnaire disability index (HAQ DI) score at week 14, proportions of patients with ACR50 and ACR70 responses and >= 75% improvement on the Psoriasis Area and Severity Index (a PASI75 response) at week 14, and change from baseline at week 24 in the total modified Sharp/van der Heijde score (SHS) with modifications for patients with PsA. Results. At week 14, an ACR20 response was achieved by 75.1% of patients in the golimumab group compared with 21.8% of patients in the placebo group (P < 0.001). Greater proportions of golimumab-treated patients had an ACR50 response (43.6% versus 6.3%), an ACR70 response (24.5% versus 2.1%), and a PASI75 response (59.2% versus 13.6%) at week 14 (P < 0.001 for all). Patients in the golimumab group had greater mean changes at week 14 in HAQ DI score (-0.60 versus -0.12; P < 0.001). At week 24, the mean change in total PsA-modified SHS was -0.4 in the golimumab group and 2.0 in the placebo group (P < 0.001). Through week 24, 40.6% of patients in the placebo group and 46.3% of patients in the golimumab group had >= 1 adverse event (AE); infections were the most common type. Conclusion. Patients receiving IV golimumab at 2 mg/kg had significantly greater improvements in the signs and symptoms of PsA and less radiographic progression through week 24. AEs were consistent with those seen with other anti-tumor necrosis factor agents.
引用
收藏
页码:2151 / 2161
页数:11
相关论文
共 50 条
  • [31] Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy
    Li, Zhanguo
    Zhang, Fengchun
    Kay, Jonathan
    Fei, Kaiyin
    Han, Chenglong
    Zhuang, Yanli
    Wu, Zhong
    Hsia, Elizabeth C.
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2016, 19 (11) : 1143 - 1156
  • [32] EFFICACY AND SAFETY OF GUSELKUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO DEMONSTRATED INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITION: WEEK 24 RESULTS OF A PHASE 3B, RANDOMIZED, CONTROLLED STUDY
    Coates, L. C.
    Gossec, L.
    Theander, E.
    Bergmans, P.
    Neuhold, M.
    Karyekar, C.
    Shawi, M.
    Noel, W.
    Schett, G.
    Mcinnes, I.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 140 - 141
  • [33] Treatment with Upadacitinib in Active Psoriatic Arthritis: Efficacy and Safety Data of the First 192 Patients from the UPJOINT Study, a Multicentre, Observational Study in Clinical Practice
    Werner, Stephanie G.
    Baraliakos, Xenofon
    Reckert, Sabine
    Bohl-Buehler, Martin
    Laliberte, Marie-Claude
    Girard, Tanya
    Jeromin, Katharina
    Baschuk, Nikola
    Fritz, Bjorn
    Bessette, Louis
    Hueber, Axel J.
    RHEUMATOLOGY AND THERAPY, 2023, 10 (06) : 1503 - 1518
  • [34] Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)
    Rubbert-Roth, Andrea
    Tak, Paul P.
    Zerbini, Cristiano
    Tremblay, Jean-Luc
    Carreno, Luis
    Armstrong, Gillian
    Collinson, Neil
    Shaw, Tim M.
    RHEUMATOLOGY, 2010, 49 (09) : 1683 - 1693
  • [35] Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study
    Leng, Xiaomei
    Lin, Wei
    Liu, Shixue
    Kanik, Keith
    Wang, Cunshan
    Wan, Weiguo
    Jiang, Zhenyu
    Liu, Yi
    Liu, Shengyun
    Zhang, Zhuoli
    Zhang, Zhiyi
    Xu, Jian
    Tan, Wenfeng
    Hu, Jiankang
    Li, Jingyang
    Liu, Ju
    Gunay, Levent M.
    Dina, Oluwaseyi
    Kinch, Cassandra
    Zeng, Xiaofeng
    RMD OPEN, 2023, 9 (01):
  • [36] SAFETY PROFILE OF BIMEKIZUMAB AT WEEK 16 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS: RESULTS FROM FOUR PLACEBO-CONTROLLED PHASE 3 STUDIES
    Poddubnyy, D.
    Gensler, L. S.
    Mease, P. J.
    Orbai, A. M.
    Warren, R. B.
    Ink, B.
    Massow, U.
    Assudani, D.
    Fleurinck, C.
    Shende, V.
    Smith, J.
    Peterson, L.
    White, K.
    Landewe, R. B. M.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1686 - 1687
  • [37] EFFICACY AND SAFETY OF GUSELKUMAB TN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO DEMONSTRATED INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITION: WEEK 24 RESULTS OF A PHASE 3B, RANDOMIZED, CONTROLLED STUDY
    Coates, Laura C.
    Gossec, Laure
    Theander, Elke
    Bergmans, Paul
    Neuhold, Marlies
    Karyekar, Chetan S.
    Shawi, May
    Noel, Wim
    Schett, Georg
    McInnes, Iain B.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2021, 27 : S106 - S107
  • [38] Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial
    Tanaka, Yoshiya
    Harigai, Masayoshi
    Takeuchi, Tsutomu
    Yamanaka, Hisashi
    Ishiguro, Naoki
    Yamamoto, Kazuhiko
    Miyasaka, Nobuyuki
    Koike, Takao
    Baker, Daniel
    Ishii, Yutaka
    Yoshinari, Toru
    MODERN RHEUMATOLOGY, 2016, 26 (04) : 481 - 490
  • [39] Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial
    Kavanaugh, Arthur
    Puig, Lluis
    Gottlieb, Alice B.
    Ritchlin, Christopher
    Li, Shu
    Wang, Yuhua
    Mendelsohn, Alan M.
    Song, Michael
    Zhu, Yaowei
    Rahman, Proton
    Mcinnes, Iain B.
    ARTHRITIS CARE & RESEARCH, 2015, 67 (12) : 1739 - 1749
  • [40] Treatment adherence, efficacy, and safety of etanercept in patients with active psoriatic arthritis and peripheral involvement in Belgium for 66 months (PROVE study)
    de Vlam, K.
    Boone, C.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2015, 33 (05) : 624 - 631